Ceria Nanoparticles Fabricated with 6-Aminohexanoic Acid that Overcome Systemic Inflammatory Response Syndrome

Han Gil Jeong, Bong Geun Cha, Dong Wan Kang, Do Yeon Kim, Wookjin Yang, Seul Ki Ki, Song I. Kim, Juhee Han, Chi Kyung Kim, Jaeyun Kim, Seung Hoon Lee

Research output: Contribution to journalArticle

Abstract

Systemic inflammatory response syndrome (SIRS) is self-destructive and uncontrollable inflammatory response of the whole body triggered by infection, trauma, or a variety of severe injuries. Although reactive oxygen species play a pivotal role in the development of SIRS, the trials with conventional antioxidants have failed to improve patient outcome. Ceria nanoparticles (CeNPs) have potent, autocatalytic reactive oxygen species scavenging activities, which may have sufficient therapeutic effects for SIRS. Herein, 3 nm CeNPs are fabricated totally in aqueous phase by using 6-aminohexanoic acid (6-AHA) and their Ce 3+ to Ce 4+ ratio is increased to enhance antioxidative properties. The obtained 6-AHA-CeNPs demonstrate strong antioxidative and anti-inflammatory effects in various biofluids and inflammatory cells. In SIRS animal models, 6-AHA-CeNPs are demonstrated to reduce multiple organ injuries and inflammation. Moreover, 6-AHA-CeNPs decrease mortality and improve clinical scores of SIRS models. These findings suggest that 6-AHA-CeNPs have potential as a therapeutic nanomedicine for SIRS.

Original languageEnglish
Article number1801548
JournalAdvanced Healthcare Materials
Volume8
Issue number9
DOIs
Publication statusPublished - 2019 May 9

Fingerprint

Aminocaproic Acid
Systemic Inflammatory Response Syndrome
Cerium compounds
Nanoparticles
Acids
Reactive Oxygen Species
Nanomedicine
Medical nanotechnology
Oxygen
Multiple Trauma
Scavenging
Wounds and Injuries
Therapeutic Uses
Antioxidants
Animals
Anti-Inflammatory Agents
Animal Models
Inflammation
Mortality
Infection

Keywords

  • 6-aminohexanoid acid
  • cerium oxide nanoparticles
  • nanotherapeutics
  • reactive oxygen species
  • systemic inflammatory response syndrome

ASJC Scopus subject areas

  • Biomaterials
  • Biomedical Engineering
  • Pharmaceutical Science

Cite this

Ceria Nanoparticles Fabricated with 6-Aminohexanoic Acid that Overcome Systemic Inflammatory Response Syndrome. / Jeong, Han Gil; Cha, Bong Geun; Kang, Dong Wan; Kim, Do Yeon; Yang, Wookjin; Ki, Seul Ki; Kim, Song I.; Han, Juhee; Kim, Chi Kyung; Kim, Jaeyun; Lee, Seung Hoon.

In: Advanced Healthcare Materials, Vol. 8, No. 9, 1801548, 09.05.2019.

Research output: Contribution to journalArticle

Jeong, HG, Cha, BG, Kang, DW, Kim, DY, Yang, W, Ki, SK, Kim, SI, Han, J, Kim, CK, Kim, J & Lee, SH 2019, 'Ceria Nanoparticles Fabricated with 6-Aminohexanoic Acid that Overcome Systemic Inflammatory Response Syndrome', Advanced Healthcare Materials, vol. 8, no. 9, 1801548. https://doi.org/10.1002/adhm.201801548
Jeong, Han Gil ; Cha, Bong Geun ; Kang, Dong Wan ; Kim, Do Yeon ; Yang, Wookjin ; Ki, Seul Ki ; Kim, Song I. ; Han, Juhee ; Kim, Chi Kyung ; Kim, Jaeyun ; Lee, Seung Hoon. / Ceria Nanoparticles Fabricated with 6-Aminohexanoic Acid that Overcome Systemic Inflammatory Response Syndrome. In: Advanced Healthcare Materials. 2019 ; Vol. 8, No. 9.
@article{b26e08de109e4392ac82ae3512127576,
title = "Ceria Nanoparticles Fabricated with 6-Aminohexanoic Acid that Overcome Systemic Inflammatory Response Syndrome",
abstract = "Systemic inflammatory response syndrome (SIRS) is self-destructive and uncontrollable inflammatory response of the whole body triggered by infection, trauma, or a variety of severe injuries. Although reactive oxygen species play a pivotal role in the development of SIRS, the trials with conventional antioxidants have failed to improve patient outcome. Ceria nanoparticles (CeNPs) have potent, autocatalytic reactive oxygen species scavenging activities, which may have sufficient therapeutic effects for SIRS. Herein, 3 nm CeNPs are fabricated totally in aqueous phase by using 6-aminohexanoic acid (6-AHA) and their Ce 3+ to Ce 4+ ratio is increased to enhance antioxidative properties. The obtained 6-AHA-CeNPs demonstrate strong antioxidative and anti-inflammatory effects in various biofluids and inflammatory cells. In SIRS animal models, 6-AHA-CeNPs are demonstrated to reduce multiple organ injuries and inflammation. Moreover, 6-AHA-CeNPs decrease mortality and improve clinical scores of SIRS models. These findings suggest that 6-AHA-CeNPs have potential as a therapeutic nanomedicine for SIRS.",
keywords = "6-aminohexanoid acid, cerium oxide nanoparticles, nanotherapeutics, reactive oxygen species, systemic inflammatory response syndrome",
author = "Jeong, {Han Gil} and Cha, {Bong Geun} and Kang, {Dong Wan} and Kim, {Do Yeon} and Wookjin Yang and Ki, {Seul Ki} and Kim, {Song I.} and Juhee Han and Kim, {Chi Kyung} and Jaeyun Kim and Lee, {Seung Hoon}",
year = "2019",
month = "5",
day = "9",
doi = "10.1002/adhm.201801548",
language = "English",
volume = "8",
journal = "Advanced healthcare materials",
issn = "2192-2640",
publisher = "John Wiley and Sons Ltd",
number = "9",

}

TY - JOUR

T1 - Ceria Nanoparticles Fabricated with 6-Aminohexanoic Acid that Overcome Systemic Inflammatory Response Syndrome

AU - Jeong, Han Gil

AU - Cha, Bong Geun

AU - Kang, Dong Wan

AU - Kim, Do Yeon

AU - Yang, Wookjin

AU - Ki, Seul Ki

AU - Kim, Song I.

AU - Han, Juhee

AU - Kim, Chi Kyung

AU - Kim, Jaeyun

AU - Lee, Seung Hoon

PY - 2019/5/9

Y1 - 2019/5/9

N2 - Systemic inflammatory response syndrome (SIRS) is self-destructive and uncontrollable inflammatory response of the whole body triggered by infection, trauma, or a variety of severe injuries. Although reactive oxygen species play a pivotal role in the development of SIRS, the trials with conventional antioxidants have failed to improve patient outcome. Ceria nanoparticles (CeNPs) have potent, autocatalytic reactive oxygen species scavenging activities, which may have sufficient therapeutic effects for SIRS. Herein, 3 nm CeNPs are fabricated totally in aqueous phase by using 6-aminohexanoic acid (6-AHA) and their Ce 3+ to Ce 4+ ratio is increased to enhance antioxidative properties. The obtained 6-AHA-CeNPs demonstrate strong antioxidative and anti-inflammatory effects in various biofluids and inflammatory cells. In SIRS animal models, 6-AHA-CeNPs are demonstrated to reduce multiple organ injuries and inflammation. Moreover, 6-AHA-CeNPs decrease mortality and improve clinical scores of SIRS models. These findings suggest that 6-AHA-CeNPs have potential as a therapeutic nanomedicine for SIRS.

AB - Systemic inflammatory response syndrome (SIRS) is self-destructive and uncontrollable inflammatory response of the whole body triggered by infection, trauma, or a variety of severe injuries. Although reactive oxygen species play a pivotal role in the development of SIRS, the trials with conventional antioxidants have failed to improve patient outcome. Ceria nanoparticles (CeNPs) have potent, autocatalytic reactive oxygen species scavenging activities, which may have sufficient therapeutic effects for SIRS. Herein, 3 nm CeNPs are fabricated totally in aqueous phase by using 6-aminohexanoic acid (6-AHA) and their Ce 3+ to Ce 4+ ratio is increased to enhance antioxidative properties. The obtained 6-AHA-CeNPs demonstrate strong antioxidative and anti-inflammatory effects in various biofluids and inflammatory cells. In SIRS animal models, 6-AHA-CeNPs are demonstrated to reduce multiple organ injuries and inflammation. Moreover, 6-AHA-CeNPs decrease mortality and improve clinical scores of SIRS models. These findings suggest that 6-AHA-CeNPs have potential as a therapeutic nanomedicine for SIRS.

KW - 6-aminohexanoid acid

KW - cerium oxide nanoparticles

KW - nanotherapeutics

KW - reactive oxygen species

KW - systemic inflammatory response syndrome

UR - http://www.scopus.com/inward/record.url?scp=85062782354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062782354&partnerID=8YFLogxK

U2 - 10.1002/adhm.201801548

DO - 10.1002/adhm.201801548

M3 - Article

C2 - 30843374

AN - SCOPUS:85062782354

VL - 8

JO - Advanced healthcare materials

JF - Advanced healthcare materials

SN - 2192-2640

IS - 9

M1 - 1801548

ER -